Literature DB >> 15183535

Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women.

Chikako Noma1, Yasuo Miyoshi, Tetsuya Taguchi, Yasuhiro Tamaki, Shinzaburo Noguchi.   

Abstract

Since it is well established that inactivation of p53 is involved in pathogenesis of breast cancer, it seems to be reasonable to assume that p53 genetic polymorphism at codon 72 (p53Arg72Pro) which affects the function of p53 might have an influence on breast cancer risk. Thus, in the present study, we have studied the association of p53Arg72Pro polymorphism with breast cancer risk. A case-control study was conducted with 191 breast cancer patients and 218 healthy female controls. p53Arg72Pro polymorphism was examined in their association with breast cancer risk after adjustment for the epidemiological risk factors. Relationship between p53Arg72Pro polymorphism and clinicopathological characteristics of breast cancers was also studied. In addition, frequency of somatic p53 mutation was compared according to the genotype of p53Arg72Pro polymorphism. p5372Pro/Pro homozygotes showed a significant increase in the risk of estrogen receptor (ER) positive breast cancer (adjusted odds ratio (OR) = 2.04, P = 0.04) as compared with p5372Arg/Arg homozygotes, whereas such an association was not found between p5372Pro/Pro homozygotes and ER negative breast cancer risk. Subset analysis according to menopausal status showed that p5372Pro/Pro homozygotes were significantly associated with ER positive breast cancer risk in postmenopausal women (adjusted OR = 3.42, P = 0.01) but not in premenopausal women. Frequency of ER positive tumors was significantly (p < 0.01) higher in breast cancer patients with p5372Pro/Pro genotype (82.8%) than those with p5372Arg/Arg genotype (54.5%). Mutational analysis of p53 in tumors showed that p5372Pro/Pro homozygotes had a lower frequency of p53 mutation (3.5%) than p5372Arg/Arg homozygotes (10.5%). It is suggested that p53Arg72Pro polymorphism is associated with ER positive breast cancer risk, especially, in postmenopausal women. The higher frequency of p53 somatic mutation in p5372Arg/Arg homozygotes than p5372Pro/Pro homozygotes is consistent with the thesis that the function of p5372Pro/Pro is impaired so that a further alteration of p53 gene is less required in p5372Pro/Pro homozygotes than p5372Arg/Arg homozygotes. Copyright 2004 Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183535     DOI: 10.1016/j.canlet.2004.03.031

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  18 in total

1.  Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.

Authors:  Patricia Rodrigues; Jessica Furriol; Eduardo Tormo; Sandra Ballester; Ana Lluch; Pilar Eroles
Journal:  Mol Cell Biochem       Date:  2013-04-06       Impact factor: 3.396

2.  TLR2∆22 (-196-174) significantly increases the risk of breast cancer in females carrying proline allele at codon 72 of TP53 gene: a case-control study from four ethnic groups of North Eastern region of India.

Authors:  K Rekha Devi; Saia Chenkual; Gautam Majumdar; Jishan Ahmed; Tanvir Kaur; Jason C Zonunmawia; Kaustab Mukherjee; Rup Kumar Phukan; Jagdish Mahanta; S K Rajguru; Debdutta Mukherjee; Kanwar Narain
Journal:  Tumour Biol       Date:  2015-07-19

3.  Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy.

Authors:  Ankita Kumari; Charu Bahl; Navneet Singh; Digambar Behera; Siddharth Sharma
Journal:  Mol Biol Rep       Date:  2016-09-10       Impact factor: 2.316

4.  Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients.

Authors:  Elaine Cristina Morari; Andre Bacellar Costa Lima; Natassia Elena Bufalo; Janaina Luisa Leite; Fabiana Granja; Laura Sterian Ward
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-19       Impact factor: 4.553

5.  The TP53 gene polymorphisms and survival of sporadic breast cancer patients.

Authors:  V Bišof; M Peričić Salihović; N Smolej Narančić; T Skarić-Jurić; J Jakić-Razumović; B Janićijević; P Rudan
Journal:  Med Oncol       Date:  2011-03-02       Impact factor: 3.064

6.  TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.

Authors:  Rym Abderrahmane; Lotfi Louhibi; Fatima Zohra Moghtit; Amina Boubekeur; Khedidja Benseddik; Abdellah Boudjema; Fouzia Benrrahal; Meriem Aberkane; Mostefa Fodil; Nadhira Saidi-Mehtar
Journal:  Pathol Oncol Res       Date:  2014-12-24       Impact factor: 3.201

7.  Breast cancer risk in relation to TP53 codon 72 and CDH1 gene polymorphisms in the Bangladeshi women.

Authors:  Samia Shabnaz; Maizbha Uddin Ahmed; Md Siddiqul Islam; Md Reazul Islam; Mir Md Abdullah Al-Mamun; Mohammad Safiqul Islam; Abul Hasnat
Journal:  Tumour Biol       Date:  2015-12-14

8.  Association of common WRAP 53 variant with ovarian cancer risk in the Polish population.

Authors:  Krzysztof Mędrek; Piotr Magnowski; Bartłomiej Masojć; Anita Chudecka-Głaz; Bogdan Torbe; Janusz Menkiszak; Marek Spaczyński; Jacek Gronwald; Jan Lubiński; Bohdan Górski
Journal:  Mol Biol Rep       Date:  2012-11-29       Impact factor: 2.316

9.  p53 codon 72 polymorphism and breast cancer risk: A meta-analysis.

Authors:  Jing Hou; Yuan Jiang; Wenru Tang; Shuting Jia
Journal:  Exp Ther Med       Date:  2013-03-20       Impact factor: 2.447

10.  Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls.

Authors:  Wenlei Zhuo; Yunsong Zhang; Zhaolan Xiang; Lei Cai; Zhengtang Chen
Journal:  J Exp Clin Cancer Res       Date:  2009-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.